Cheating Death: The Heart Attack Survivor
Case Presentation
Let's say you have a heart attack and you're lucky enough to make it to your local hospital's catheterization laboratory (cath lab) in a timely fashion—well under the "door to balloon time" goal of 120 minutes from contact with Emergency Medical Services (EMS) to balloon inflation—to receive a "drug eluting stent (DES)" in your left anterior descending artery (LAD, sometimes called the "Widowmaker"). Your symptoms resolve and you sleep well overnight. The attending cardiologist rounds on you the next morning, tells you your troponins were minimally elevated and your echo shows no gross heart muscle damage. She deems you fit for discharge.
Whew! That was a close one! After some brief education and perhaps some lecturing about this teachable moment, you feel thankful to be alive and motivated to change habits. You thank all of the caretakers and your friend or loved one takes you home. Quick, easy and some might say it's like "drive thru" medicine!
Flying Under the Radar
You might ask: "If we already know who they are, why on Earth would they be flying under our radar?"
Turns out that despite being identified by a heart attack, the highest likelihood of having another heart attack is within the ensuing first year. We call this "residual risk."
Why? Multiple reasons, but in a nutshell—undertreatment of the disease of atherosclerosis. Despite a plethora of published guidelines, scientific statements and expert consensus documents, too many (some studies find it's the overwhelming majority) of secondary prevention patients fail to receive intense treatment.
As an example, despite recommendations for high intensity statins published in guidelines more than 20 years ago, implementation is embarrassingly low.
The evolution of atherosclerotic cardiovascular disease (ASCVD) treatment has reached a point in medicine where we are capable of not only halting the progression of disease, but potentially reversing it in the majority of patients. There will always be "residual risk" (which, by the way, keeps the study and practice of medicine interesting). But if you fail to employ the latest treatments, or as in the case above, not employing any statin in half of the patients, it's like taking a time machine back to 1986 medicine (statins first arrived in 1987).
CardioAdvocate Checklist for Heart Attack Survivors
Lipid Goals for Secondary Prevention
See also: What's Your ApoB? A General Approach to Lipid Management
| Biomarker | Target Goal | Notes |
|---|---|---|
| Apolipoprotein B (ApoB) | < 65 mg/dL (2019 ESC/EAS) < 50 mg/dL (Expert Opinion) |
Recognized as the optimal biomarker over LDL-C and Non-HDL-C |
| Non-HDL-C | < 80 mg/dL | Total cholesterol minus HDL-C; reflects all atherogenic particles |
| LDL-C | < 55 mg/dL AND ≥ 50% reduction from baseline | IMPORTANT: Both targets must be met. Example: if baseline LDL-C is 72 mg/dL, goal is < 36 mg/dL. Now endorsed by both 2026 ACC/AHA and 2019 ESC/EAS guidelines. |
| LDL-C (very high risk) | < 40 mg/dL | Patients with ASCVD with another vascular event within 2 years |
| LDL-C (advanced atherosclerosis) | 20-40 mg/dL | Based on PCSK9i trials (FOURIER, ODYSSEY) and plaque regression data (GLAGOV with mean LDL-C 39 mg/dL). See also: Very Low LDL Meta-Analysis (JACC). State of the Art Review |
| Triglycerides | < 150 mg/dL | Not a direct "goal" per se, but important for assessing discordance with LDL-C |
Lipid Lowering Drug Therapy
High Intensity Statin (Preferred)
- Atorvastatin 40-80 mg daily (generic)
- Rosuvastatin 20-40 mg daily (generic)
Additional Non-Statin Therapies
- Ezetimibe 10 mg daily (generic)
- 10-15% LDL-C reduction as monotherapy
- 20-25% additional LDL-C reduction when combined with statin
- PCSK9 Inhibitors (monoclonal antibodies) – Approximately 50-70% LDL-C reduction
- Evolocumab (Repatha) 140 mg SQ every 2 weeks or 420 mg SQ every 4 weeks
- Alirocumab (Praluent) 75 or 150 mg SQ every 2 weeks or 300 mg SQ every 4 weeks
- Recommended when LDL-C ≥ 70 mg/dL despite max tolerated statin + ezetimibe (see FOURIER and ODYSSEY Outcomes)
- Inclisiran (Leqvio) 240 mg SQ every 6 months
- Small interfering RNA (siRNA) mechanism
- 2 initial doses 3 months apart, then 2 doses per year
- Bempedoic Acid (NEXLETOL) 180 mg daily
- NEXLIZET (bempedoic acid + ezetimibe 180/10 mg) provides ~38% LDL-C reduction
- Enlicitide (Lipfendra) 20 mg daily — Oral PCSK9 Inhibitor (NEW: FDA approved July 16, 2026)
- First oral PCSK9 inhibitor — removes the injection barrier
- 56-59% LDL-C reduction in clinical trials (CORALreef Lipids, NEJM 2025; CORALreef HeFH, JAMA 2026)
- Once-daily tablet; same magnitude of LDL lowering as injectable PCSK9i
For Acute Coronary Syndrome Patients
- PCSK9i should be initiated early, ideally while in hospital (Class IIa ESC/EAS)
- Repeat lipids at 4-6 weeks after max statin + ezetimibe. If not at goal, add PCSK9i (Class I ESC/EAS)
Icosapent Ethyl (Vascepa) 1g Twice Daily
- EPA-only Omega-3 Polyunsaturated Fatty Acid (PUFA)
- Pharmaceutical grade—this is a drug, not a supplement. Big difference:
- Drugs are FDA approved and undergo rigorous scientific investigation, scrutiny, and peer-reviewed clinical trials
- Supplements are "foods"—not the same as "Over The Counter"—not regulated by the FDA and not required to list ingredients accurately
Antiplatelet Therapy
- Aspirin 81 mg daily, OR
- Clopidogrel 75 mg daily (if allergic or contraindicated to aspirin)
Lifestyle Interventions
Diet/Nutrition
- DASH or Mediterranean Diet recommended
Exercise
- 150-300 minutes per week of modest activity (brisk walking), OR
- 75-150 minutes per week of vigorous activity
Environmental Toxins
- Stop smoking! Continuing to smoke guarantees a repeat offense. Even if you do everything else above but continue to smoke, we will have no chance in stopping the disease.
- Avoid Plastics: A recent study published March 7, 2024, in NEJM demonstrated a 4.5 times increased risk of heart attack, stroke, and all-cause mortality in those found to have plastics in their carotid artery, compared to those who did not. Until we know more, choose packaging that reduces the risk of ingesting plastics.
Deep Dive: Why Me?
After surviving a heart attack, patients understandably want answers. The question typically comes in the form of "Why did I have a heart attack?" or "I've been seeing my doctor regularly—wouldn't this have been detected?"
The answers are complicated but best summed up by a slide from Dr. Matthew Budoff, preventive cardiologist:
Mediocre doctors treat the disease before evident
Inferior doctors treat the full-blown disease"
– Huang Dee Nai-Chang (2600 BC, 1st Chinese Medical Text)
Atherosclerosis develops over several decades. There are multiple opportunities along the way to recognize risk factors, identify its presence, and get in front of the disease. But once it fully manifests, it becomes much more challenging to stabilize or reverse. We now have the tools and it can be done.
Historical Evolution of ASCVD Treatment
1964: US Surgeon General issues report concluding smoking was "probable" cause of coronary heart disease.
1987: Lovastatin (Mevacor) released—arguably the greatest therapeutic advancement in modern medicine beyond vaccinations and antibiotics. In the 1980s-1990s, the goal was simply to slow disease progression.
2004 (REVERSAL Trial): First evidence of halting plaque progression using high-intensity statin (atorvastatin 80 mg achieving mean LDL-C ~70 mg/dL). Plaque regression seen in small percentage of patients.
2006 (ASTEROID Trial): Evidence of plaque regression using rosuvastatin 40 mg achieving mean LDL-C of 60 mg/dL.
2016 (GLAGOV Trial): Evolocumab (Repatha) demonstrated plaque regression in approximately 2/3 of patients achieving atheroma regression at mean LDL-C of 36 mg/dL, versus placebo (statin only) showing no regression at mean LDL-C of 93 mg/dL.
What Causes Atherosclerosis?
Blood cholesterol, trafficked in "atherogenic" lipoprotein particles—predominantly Low Density Lipoprotein (LDL)—is causal to atherosclerosis all by itself. This fact is recognized by every cardiovascular organization in the world.
Cumulative exposure to atherogenic lipoproteins is all that is needed to produce atherosclerosis.
By checking someone's blood concentration of LDL-C in mg/dL, which is a surrogate for LDL particles, we get a good approximation of what has been traveling through the bloodstream of that individual every second of their life. That lifetime exposure to ApoB-containing particles (atherogenic particles) is largely what drives ASCVD risk.
In a population, the higher the LDL-C, the higher the risk of atherosclerosis. But even "normal LDL-C" levels are plenty. This comes as a surprise to many patients following their first heart attack when they declare: "But I've always been told my cholesterol was normal!"
Bell-shaped curves showing cholesterol levels of those admitted with their first heart attack compared with those of the general population are nearly superimposable. The only levels of LDL-C that essentially guarantee a life free of atherosclerosis are those in the pediatric range of 20-40 mg/dL. Heart disease is the #1 killer for a reason—it's damn common.
Why Are People Still Dying from This Preventable Disease?
Underrecognition of Disease
- Access: For many, it's an issue of access to healthcare. Men are less likely to seek it out; women are less likely to be identified even when they do seek it out.
- Screening: Appropriate screening is available but not implemented regularly. Traditional risk calculators often fall short—3 out of 4 younger patients presenting with their first cardiac event would have never qualified for a statin using standard risk calculators. The AHA's PREVENT calculator has replaced the older Pooled Cohort Equations, adding kidney function and metabolic factors, though significant gaps remain for younger patients.
- Coronary Artery Calcium Scores offer superior screening when used on top of traditional risk calculators with highest Net Reclassification Index and highest C-statistic, and even benefit low-risk patients.
- Cost: Many patients lack insurance or cannot afford copays to see their doctor or obtain coverage for screening tests. Despite calcium scores being recognized in multiple guidelines, insurance companies refuse to cover them. However, most calcium score testing has been made affordable ($79-$199).
Undertreatment of Disease
- Guideline Confusion: There are many guidelines—some more conservative than others. This impacts cholesterol treatment goals/thresholds; choosing a more conservative goal runs the risk of undertreatment. The 2026 ACC/AHA Guideline has narrowed this gap, adopting < 55 mg/dL LDL-C targets for very high-risk patients — aligning more closely with European guidelines.
- Misinterpretation of Recommendations: Most guidelines recommend high-risk patients achieve a particular threshold or goal LDL-C AND > 50% lowering from baseline. Many forget that last part—meaning a patient may have an LDL-C of 72 mg/dL and are placed on a low/modest regimen aimed at getting below 70 mg/dL (wrong!).
- Adherence Issues:
- Patients: More than 50% of patients prescribed statins following an ASCVD event will stop taking their statin by 1 year.
- Providers: CMS does not declare LDL-C a "Quality Measure," so healthcare providers and systems are not held accountable for achieving LDL-C goals.
- Statin Intolerance: Way over-diagnosed. 90% of patient complaints of statin myalgias are attributable to the "nocebo" effect. But 10% are real, and many patients are simply labeled "statin intolerant" without treatment alternatives implemented.
- Insurance Denials: Despite a 60% cost reduction for PCSK9i from ~$15,000/year to $5,500/year in 2018, insurance companies continue to deny coverage of life-saving non-statin therapies.
- Provider Education: It takes, on average, 13 years for published guidelines to infiltrate mainstream clinical practice. Medicine moves slowly.
- Over-reliance on LDL-C Discordance: LDL-C needs to be a "Quality Measure" because it's by far the most commonly used lipid biomarker. However:
- When TGs are high and HDL-C is low, LDL-C is discordant and may drastically underestimate LDL particles and risk.
- Non-HDL-C is a better biomarker than LDL-C when triglycerides are elevated (> 150 mg/dL), yet few clinicians calculate it or know what it means.
- ApoB is better when recognizing residual risk in the presence of discordance.
- Ignoring Triglycerides: Residually elevated TGs are a prerequisite for icosapent ethyl (Vascepa), a therapy that can reduce ASCVD events by an additional 25% (REDUCE-IT trial). See also: Something Smells Fishy — Fish Oil.
Even Lower Is Even Better, For Even Longer
- In patients with established ASCVD or prior acute coronary syndrome, the latest clinical trials demonstrate no LDL-C threshold for which there was not an even greater clinical benefit. Meaning: the lower the achieved level, the greater the risk reduction—even with LDL-C levels < 20 mg/dL.
- Patients with diabetes derive a greater overall cardiovascular benefit from LDL-C reduction than those without diabetes, reflecting their higher absolute risk (IMPROVE-IT).
- Mendelian genetics studies demonstrate earlier treatment in those with genetic variants suggests reduction in ASCVD events.
Bottom Line
The Bottom Line
Don't Be a Repeat Offender. Our mission at CardioAdvocate.com is to eradicate atherosclerotic cardiovascular disease in everyone. We wish to make published resources and expert recommendations more available, thereby facilitating more informed, personalized discussions.
In our highest-risk patients, such as the heart attack survivor, we tend to align ourselves with the most aggressive lipid-lowering recommendations, including expert consensus opinion, rather than the more conservative recommendations of others, despite their popularity.
We agree with the statement from the 2019 Joint ESC/EAS Dyslipidemia Guidelines: "LDL-C levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients."
Better put in this expert White Paper call to action (Eliminating Atherosclerotic Cardiovascular Disease Residual Risk): "Residual risk is a euphemism for failure to prevent."
As Dr. John Kastelein stated at the ESC meeting in 2019: "LDL-C is a toxic agent that in principle needs eradication, but in practice needs early, long-term and aggressive lowering."
The 2026 ACC/AHA Dyslipidemia Guideline has moved the field closer to this position, lowering the LDL-C threshold for non-statin addition to < 55 mg/dL for very high-risk patients and formally endorsing ApoB and non-HDL-C as co-primary targets. It also incorporates five new therapies, including Lipfendra (enlicitide), the first oral PCSK9 inhibitor. In our view, simply having any major ASCVD event is plenty and requires the most aggressive and urgent action ASAP!
Here is a great review of the Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention.
Related CardioAdvocate Content
- What's Your ApoB? A General Approach to Lipid Management
- Coronary Artery Calcium (CAC) — Superior screening for atherosclerosis
- Hiding in Plain Sight: Familial Hypercholesterolemia (FH) — Genetic cause of premature ASCVD
- Little Napoleon Complex: Lipoprotein(a)
- The Sweet Spot: Diabetes and Cardiovascular Disease
- Atherogenic Triad — Understanding LDL-C/ApoB discordance
- Something Smells Fishy: Fish Oil — Icosapent ethyl and triglyceride management
- Brain Attack: How Recognizing Heart Disease May Save Your Brain
- There's an App for That: Cardiovascular Risk Calculators
- Statins: Apocalypse or Pleiotropic Nirvana
- Follow the Leader: ApoB & LDL-C Lipid Guidelines
